Imugene (ASX:IMU) to present new PD1-Vaxx data at WCLC 2022

Highlights

• Imugene Limited will be presenting new PD1-Vaxx data at the upcoming IASLC 2022 World Conference on Lung Cancer.
• The abstract will elaborate on ‘PD1-Vaxx, a B-Cell Immunotherapy as monotherapy or in combination with Atezolizumab, in non-small cell lung cancer patients.
• Professor Michael Boyer from Chris O’Brien Lifehouse Hospital will be the Presenting Author of the abstract.

Leading clinical stage immuno-oncology company Imugene Limited (ASX:IMU) has announced that it will be presenting its new PD1-Vaxx data at the upcoming IASLC 2022 World Conference on Lung Cancer (WCLC 2022).

The new data from its Phase I IMPRINTER trial in non-small cell lung cancer (NSCLC) patients has been selected for a poster presentation at the event, which will be conducted online as well as in-person in Vienna, Austria from 6 August to 9 August.

Read here for information on Phase 1 clinical trial of PD1-Vaxx

What is PD1-Vaxx?

PD1-Vaxx is a B-cell activating immunotherapy. It is being developed for treating tumours (such as lung cancer) by interfering with PD-L1/PD-1 binding and interaction. It has been formulated to build an anti-cancer effect akin to Opdivo®, Keytruda®, and several other immune checkpoint inhibitor monoclonal antibodies.

The IMPRINTER trial by the Company is an open-label dose escalation study of PD1-Vaxx as monotherapy (Phase 1) or in combination with atezolizumab (Phase 1b) in adults with PD-L1 expressing NSCLC.

Image Source: Company Website

Click here to know more about PD1- Vaxx abstract published at ASCO 2022

Key details of the poster presentation

The abstract to be presented at WCLC 2022 has been titled:

“Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer.”

The session, on the other hand, will be titled:

‘Metastatic Non-small Cell Lung Cancer – Immunotherapy.’

Professor Michael Boyer (M.D., MBBS, FRACP, PhD) from Chris O’Brien Lifehouse Hospital has been selected as the Presenting Author of the abstract.

The abstract to be used for the poster has been made live on wclc2022.iaslc.org from 6:00 PM CEST on 12 July 2022. It will also be released on the Company’s website.

An overview of WCLC

The World Conference on Lung Cancer (WCLC) is one of the most distinguished international gatherings of researchers, clinicians, and scientists working in the field of lung cancer and thoracic oncology.

The conference is organised every year by the International Association for the Study of Lung Cancer (IASLC). IASLC represents a high-end network of over 8,000 lung and thoracic cancer specialists from varied disciplines involved in the study and eradication of lung cancer and other thoracic malignancies.

Imugene shares are trading at A$0.22, as at 11:30 AM AEST.